Heparin Administration During Radial Artery Cannulation in Patients on Enoxaparin for Acute Myocardial Infarction

Rationale for Recommendation

The American College of Cardiology and American Heart Association recommend that patients receiving enoxaparin for acute myocardial infarction should not receive additional heparin during radial artery cannulation, as it increases bleeding risk without providing additional clinical benefit 1
The American College of Cardiology and American Heart Association advise against giving additional anticoagulants to patients who are already receiving one form of anticoagulant, to minimize bleeding risk 1

If the radial artery cannulation is performed 8-12 hours after the last subcutaneous enoxaparin dose, an additional intravenous dose of 0.3 mg/kg enoxaparin may be considered, according to the American College of Cardiology and American Heart Association guidelines 1, 2
For patients who received enoxaparin within the previous 8 hours, the anticoagulant effect is still present and adequate for the procedure, as stated by the American College of Cardiology and American Heart Association 1

The American College of Cardiology and American Heart Association note that low-molecular-weight heparins like enoxaparin have little effect on measurements of activated clotting time (ACT), so ACT should not be used as a guide to anticoagulation therapy in these patients 1
For patients on enoxaparin, monitoring for bleeding complications at the access site is more important than routine ACT monitoring, according to the American College of Cardiology and American Heart Association 1, 3

The European Society of Cardiology recommends that when enoxaparin is used as the primary anticoagulant for STEMI, it should be maintained throughout the procedure without adding unfractionated heparin 4, 5
Switching between different anticoagulant therapies during the index admission increases bleeding risk, as stated by the American College of Cardiology and American Heart Association 1, 2

Adding unfractionated heparin to a patient already on enoxaparin significantly increases the risk of bleeding complications, particularly at vascular access sites, according to the American College of Cardiology and American Heart Association 1, 6
Major bleeding complications are associated with increased mortality in acute MI patients, making it crucial to avoid unnecessary additional anticoagulation, as noted by the American College of Cardiology and American Heart Association 3